GLP-1 Competitive Market — July 10, 2026
|
Hengrui’s Kailera-partnered oral GLP-1 posted Phase 3 China data the same week Novo Nordisk launched oral semaglutide in the UK, turning the obesity-pill race into a three-front global contest against Lilly’s already-approved orforglipron (Foundayo).
Today’s top developments:
|
What to Watch
- Kailera Phase 3 readout — watch for full HbA1c reduction and weight-loss percentages from the Hengrui trial within 60 days; those numbers decide whether a US IND filing is credible or the asset stays a China-only commercial story.
- Orforglipron uptake vs Novo’s US rollout — with Foundayo FDA-approved and on the US market since April 2026, Lilly has already won the oral-approval timing race, so formulary wins and access now decide share against Novo’s forthcoming US oral semaglutide launch.
- Dr. Reddy’s API remediation — the remediation timeline and FDA inspection outcome will signal whether generic semaglutide reaches US pharmacies in 2026 or slips to 2027, a difference worth billions in Novo branded revenue retention.
- Vivani implant depot data — the deal becomes a real competitive signal when Vivani discloses Phase 1 dosing-duration data; a multi-month depot would reset chronic obesity adherence economics for a segment Lilly has no disclosed program to match.
This brief highlights the edition’s top stories. Read the full July 10, 2026 edition → for all stories and analysis — or browse the GLP-1 Competitive Market archive.